Background
==========

Asthma is a complex chronic disease of the airway, with notable airflow obstruction, eosinophilic inflammation, bronchoconstriction, and mucus hypersecretion \[[@B1]\]. Asthma and allergy (asthma/allergy) disproportionately burden ethnic minority children in the United States, African Americans in particular \[[@B2]-[@B4]\]. Asthmatic individuals of African ancestry have also been characterized with higher IgE levels, higher dependence on treatment, and experience more severe clinical symptoms compared to Whites \[[@B2]\]. Socioeconomic and environmental factors likely contribute to this disparity, but biological influences may play a discerning role.

Evidence exists for genomic features contributing to asthma pathogenesis, which in part relates to innate immunological characteristics such as variation in host defense genes \[[@B5]\]. As conveyed in Peden DB 2002, with rapid urbanization over the last few decades, some scientists believe that genes previously protecting humans from parasitic infection may now contribute to a \'misdirected\' response to environmental agents \[[@B6]\]. Individuals residing in lower socioeconomic urban environments may experience a higher burden of environmental risk factors for allergy or asthma. Thus, evaluating genetic susceptibility to asthma/allergy in such vulnerable populations can help to direct public health prevention and treatment efforts.

A variety of review papers describe genes associated with allergy/asthma \[[@B6]-[@B10]\]. Ober et al. \[[@B7]\] list genes associated with asthma or atopy in more than 10 studies. This study evaluated 8 of these genes (*IL4, IL13, TNF-α, HLA-DRB1, HLA-DQB1, FCER1B/MS4A2, CD14, ADAM33*) as well as 3 glutathione-s-transferase genes (*GSTM1, GSTP1*, and *GSTT1*) for association with asthma/allergy among urban-residing African Americans. We note some key aspects of the biological significance of the genes evaluated.

Many of these genes play roles in the Th2 response to antigens, airway reactivity, or non-specific modulation of inflammation \[[@B6]\]. The Th2 response is more characteristic of asthma in children compared to adults \[[@B6],[@B11]\] and typically accompanied by elevated immunoglobulin E (IgE) response to allergen \[[@B12]\]. Genes within the chromosome 5q cytokine cluster have demonstrated strong associations with asthma/allergy, most notably for *IL4*and *IL13*\[[@B2],[@B7],[@B13]-[@B17]\]. Associations with total serum IgE have also been observed, but with variable findings across ethnicity \[[@B18]\]. Also located on chromosome 5, the C-159T single nucleotide polymorphism (SNP) within the cluster of differentiation (*CD14*) gene has been associated with asthma, asthma severity \[[@B16],[@B19]\], and total serum IgE \[[@B20],[@B21]\]. The CD14 cell surface receptor mediates host interactions with endotoxin \[[@B11]\], suggesting a role in response to environmental stress. Another gene encoding a proinflammatory cytokine is tumor necrosis factor alpha (*TNF-α*), which has been associated with eosinophilic inflammation during lower respiratory tract infection with respiratory syncytial virus (RSV) in children \[[@B22]\].

Relevant to airway reactivity, a disintegrin and metalloprotease 33 (*ADAM33*) is expressed in bronchial tissue and whole lung \[[@B23],[@B24]\]. *ADAM33*SNPs have been associated with airway remodeling and bronchial hyper-responsiveness \[[@B25]\], but have varying associations with asthma/allergy and total serum IgE across ethnic populations \[[@B16],[@B23],[@B26]\].

Human Leukocyte Antigen (*HLA*) class II genes relate to non-specific modulation of inflammation. *HLA-DRB1*and *HLA-DQB1*SNPs and haplotypes have been associated with a higher risk of toluene diisocyanate-induced occupational asthma \[[@B27]\], total serum IgE in Iranian subjects \[[@B28]\], atopy in Northern Chinese \[[@B29]\], Dermatophagoides Spp.-sensitive asthma in Venuezuelan individuals \[[@B30]\], and asthma severity in Whites in the United States \[[@B31]\], suggesting a broad role for these genes in asthma pathogenesis across ethnic groups.

The high affinity multimeric surface receptor for IgE (Fcepsilon R1beta) is essential for IgE-mediated acute allergic response, and is thereby relevant for asthma pathogenesis \[[@B32]\]. Altered transcription of FcepsilonRlbeta correlates to the MS4A2 membrane-spanning 4-domains, subfamily A, member 2 (*MS4A2*), also known as \"Fc fragment of IgE, high affinity I, receptor for beta polypeptide (*FCER1B*)\". *MS4A2*SNPs and haplotypes have been associated with asthma in various populations \[[@B33]-[@B35]\].

Outside of the host immune response framework are the glutathione S-transferase (GST) genes, a superfamily of genes that catalyze the conjugation of reduced glutathione to electrophilic and hydrophobic compounds \[[@B36]\]. The conjugation of glutathione is important for the metabolism or detoxification of therapeutic drugs, environmental toxins, and products of oxidative stress, relevant to asthma \[[@B37],[@B38]\]. A recent meta-analysis of GST genes and asthma phenotypes reported that *GSTM1*and *GSTT1*showed increased asthma risk associated with the null genotype but that heterogeneity across studies and publication bias was a major limitation \[[@B39]\]. In this paper, we consider key asthma candidate genes for association with asthma and allergy phenotypes among African American children living in Detroit, Michigan.

Methods
=======

Study population and measurements
---------------------------------

This study involved participants of the Mechanistic Indicators of Asthma (MICA) study, conducted by the United States Environmental Protection Agency between November 2006 and January 2007 in Detroit, Michigan, as previously described \[[@B40],[@B41]\]. This was a cross-sectional study based on a stratified sample of children using two strata: children with asthma and children without asthma, selected in an approximately 1:1 ratio. A total of 205 children age 9-13 years old participated in the clinical study. In order to reduce the genetic heterogeneity of subjects in our analysis, while maximizing the total number of subjects studied, only African American children (N = 141) were selected for analysis. The study design and protocols were approved by the Institutional Review Boards at Henry Ford Health System (Detroit, MI), Westat Inc. (Rockville, MD), and the University of North Carolina at Chapel Hill (Chapel Hill, NC - US EPA\'s IRB of record). Written consent was obtained from guardians, and written assent was obtained from each child, with an oral review of both consent and assent prior to study enrollment.

For the analyses presented in this paper, hospital records were evaluated to determine doctor diagnosis of asthma for each study participant. To verify genetic associations with doctor diagnosis, two additional variables were created based on parental questionnaire data: current asthma (yes/no), and medication use (yes/no). Current asthma was defined based on the question \"Have you had an asthma attack within the last 12 months?\" Medication use was defined based on subject reports of asthma medication use.

Allergy-related traits were considered as separate phenotypes. This included total serum IgE, allergen-specific IgE (Phadiatop), testing positive for food allergens based on IgE levels, and absolute eosinophils. Total IgE was measured in serum samples using the ImmunoCAP 250 autoanalyzer (Phadia, Portage, MI, USA). Allergen specific IgE was measured in serum using a multi-allergen screen, which detects the presence (positive/negative) and relative level of antibody specific IgE for a panel of at least 15 common aeroallergens expressed as the Phadiatop level. The food allergen screening test included the 6 most common allergy-provoking foods according to the Food and Drug Administration: cows\'s milk protein, egg white, wheat, codfish, peanut, and soybean. Eosinophil antibodies were measured in blood samples collected from nonfasting children using standard methods as mandated by Clinical Laboratory Improvement Amendments (CLIA).

Genotyping
----------

A total of 53 SNPs were selected for genotyping. The candidate SNPs for this study were selected based upon: 1) a literature search for gene regions having multiple, independently-replicated associations with asthma, 2) published variability within African ancestry populations, 3) minimal evidence of LD within African ancestry populations, and 4) methodological considerations. For the first criterion, the primary source for the original SNP search was Ober et al., 2006 \[[@B7]\]. For the second criterion, the SNPs were selected by querying NCBI databases for polymorphisms with minor allele frequency \> 10% in African ancestry samples. This was done because approximately 85% of the individuals in the MICA study are African American, only African Americans were analyzed in this report, and as noted in Chang et al. 2009 \[[@B42]\], African ancestry groups have substantially different allele frequencies compared to Whites for some variants. For the third criterion, although we aimed to select SNPs with as little LD as possible, this could not be obtained for all of the genes evaluated. For the fourth criterion, implemented due to methodological considerations of the available genotyping technology, we preferentially chose SNPs within regions of low surrounding SNP density. This fourth criterion was necessary for the HLA gene regions.

Total genomic DNA was isolated from white blood cell pellets using the QiagenFlexiGene DNA kit (Qiagen, Valencia, CA). Additionally, blood clot samples were homogenized using a PowerGen 125 homogenizer (Fisher Scientific, Waltham, MA) and total gDNA was isolated from the homogenate using the QiagenFlexiGene DNA kit. Quantitation of gDNA for each sample was performed using the Nanodrop-1000 (Nanodrop Technologies, Wilmington, DE). Pre-Designed TaqManSNP Genotyping Assay, Custom TaqMan SNP Genotyping Assay or TaqMan Drug Metabolism Genotyping Assay (Applied Biosystems, Inc., Foster City, CA) was selected and designed for each SNP of interest using manufacturer\'s specificity protocol. Custom TaqMan SNP sequences were submitted via FileBuilder software (Applied Biosystems, Inc.) for assay design. Pre-Designed and Custom TaqMan SNP Genotyping Assays were run with TaqMan Genotyping Master Mix (Applied Biosystems, Inc.) according to the manufacturer suggested cycling conditions. The TaqMan Drug Metabolism Genotyping Assays were run with TaqMan Universal PCR Master Mix (Applied Biosystems, Inc.), also according to the manufacturer suggested cycling conditions. SNP genotypes were determined using 1.0 - 5.0 ng of gDNA template and suggested master mix on the ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Inc.). All SNP PCR runs contained an internal no-template control in order to determine the absence of cross contamination. SNP genotyping was performed in duplicate for ten percent of the DNA samples as a quality control measure to ensure identical genotypes between identical samples. Mismatched genotypes were run a third time to resolve discrepancies.

SNPs missing more than 3% of genotype results and individuals missing more than 10% of their data were excluded from further analyses. Remaining SNPs were tested for consistency with Hardy-Weinberg Equilibrium (HWE) among non-asthmatics using a threshold *p*-value of 0.001. Statistical quality control was completed using *PLINK*version 1.06 \[[@B43],[@B44]\].

Statistical analysis
--------------------

Continuous outcomes (total serum IgE, Phadiatop, food allergen-specific IgE, and eosinophils) were log-transformed and assessed for normal distribution using the Shapiro-Wilk test. Log-transformed Phadiatop, food allergen-specific IgE, and eosinophils did not approximate normal distribution and were evaluated as the dichotomous terms based on clinical cut-points used in other studies. Specifically, subjects with Phadiatop values ≥ 0.35 kIU/L were designated as atopic \[[@B41]\]; subjects with food allergen-specific IgE ≥ 0.35 kIU/L were classified as having tested positive for a panel of food allergens \[[@B45]\]; and subjects with absolute eosinophils ≥ 0.40 K/uL were categorized as having eosinophilia.

The association between each variant and asthma/allergy was evaluated through linear regression for continuous dependent variables (total serum IgE) or logistic regression for dichotomous dependent variables (asthma, atopy, testing positive for food allergens, and eosinophilia), following an additive genetic model. False discovery rate (FDR) was employed to correct for multiple testing \[[@B46]\]. A Q value ≤ 0.25 was used to indicate the minimum FDR where the association was considered significant. Analyses were completed using *PLINK*\[[@B43],[@B44]\] and *R*version 2.12.0 \[[@B47]\]. Linkage disequilibrium (LD) across SNPs was examined for each chromosome or gene in *Haploview*version 4.1 \[[@B48]\]. For perspective, genotyped SNPs were evaluated for LD with HapMap SNPs from the individuals of African ancestry from the South West United States (ASW) population.

Significant SNP associations were followed up with haplotype analyses. SNPs were phased in *PLINK*\[[@B43],[@B44]\] using the expectation-maximization (E-M) algorithm to assign individual haplotypes. Haplotypes were then evaluated for association with asthma/allergy through linear and logistic regression. To evaluate the consistency of haplotype estimation and association across software, *PHASE*version 2.1 \[[@B49],[@B50]\] and *Haplostats*version 1.4.4 \[[@B51]\] were employed to estimate haplotype assignments per individual and haplotype associations with asthma related traits, respectively. *Haplostats*haplo.scan \[[@B52]\] was implemented to identify the locus or loci within each haplotype demonstrating the strongest association with a particular trait. All haplotype analyses were run if the genes had one or more statistically significant SNP associations with the phenotypes of interest, after correction for multiple testing. FDR was also applied to the haplotype analyses. Age, sex, body mass index, and urinary cotinine levels were evaluated for effect measure modification using the Breslow-Day test of homogeneity of effect estimates across covariate categories. Confounding was subsequently evaluated using the percent change in effect estimate criterion \[[@B45],[@B53]\].

In addition to the haplotype analyses, SNP association analyses were complimented by constructing a genetic risk score (GRS), using a linear weighting of 0, 1, or 2 for genotypes containing 0, 1, or 2 risk alleles, respectively. For this model only, risk alleles were considered those that increased the risk of asthma in the independent SNP models. For example, because rs1871042 T corresponded to a lower risk of asthma, rs1871042 C was considered the risk allele for the GRS. The purpose of the GRS was to assess the cumulative effect of the key SNPs in our study on the odds of asthma in this population. A GRS has been used in studies of heart disease and diabetes using a variety of methods \[[@B54]-[@B57]\]. We followed similar methodology to that of a study describing a GRS to predict type 2 diabetes \[[@B58]\]. The program *Tagger*\[[@B59]\] was employed to select a minimal set of SNPs from each gene. Selected SNPs were considered independent and equally weighted. The GRS was tested for normal distribution using the Shapiro-Wilk normality test and a trend test was applied to evaluate the linearity of the relationship between the number of risk alleles and the odds of asthma.

Results
=======

Quality control
---------------

Among the 10% of samples run in duplicate, 100% obtained identical results. A total of 41 of the 53 SNPs (77%) passed statistical quality control. Association with asthma/allergy was evaluated for the following genes (SNPs): *GSTM1*(rs17672 C/T, rs412543 G/C, rs3815029 G/C), *IL13*(rs1800925 C/T, rs1295686 A/G, rs20541 C/T, rs848 G/T, rs2069750 G/T), *IL4*(rs2070874 C/T, rs734244 G/A, rs2243267 G/C, rs2243270 G/A, rs2243290 C/A), *CD14*(rs2563298 C/A, rs5744456 T/A, rs2569190 G/A, rs2569191 T/C, rs3138078 G/T), *TNF*(rs1800629 G/A, rs3093662 A/G, rs3093664 A/G, rs3093665 A/C, rs3093668 G/C), *HLA-DRB1*(rs9269701 G/A, rs9269743 A/G, rs9269841 G/A), *HLA-DQB1*(rs4993986 C/G), *MS4A2*(rs574700 C/T, rs1441586 T/C, rs556917 A/T, rs502581 C/A, rs502419 G/A), *GSTP1*(rs6591256 A/G, rs17593068 G/T, rs1695 A/G, rs1871042 C/T, rs947895 C/A), *ADAM33*(rs2787094 G/C, rs543749 G/T, rs44707 A/C, rs2271511 C/T), and *GSTT1*(null vs. present genotype).

Demographics and phenotypic/genotypic differences by ethnic group
-----------------------------------------------------------------

Among the 141 individuals analyzed, 63 (44.7%) were female and 51 (36.2%) had a body mass index of 25 or higher. A total of 64 (49.6%) individuals were asthmatic, 92 (66%) atopic, 54 (39.7%) tested positive for a panel of food allergens, and 24 (17%) were designated as having eosinophilia. Of the 53 SNPs subjected to quality control, 12 SNPs were excluded due to missing \> 3% of genotyping data (N = 7) or failed HWE (N = 5). Information on the remaining 41 SNPs and *GSTT1*-null variant was available for 141 African American subjects. The mean total serum IgE was 4.63 kU/L (standard deviation = 1.62 kU/L). Total serum IgE, atopy, testing positive for food allergens, and eosinophilia were significantly associated with asthma (Table [1](#T1){ref-type="table"}) and evaluated as outcomes in separate statistical models. No effect measure modification by covariates was observed. Sex was found to be the only significant confounder in the SNP and haplotypes models and was included as a covariate.

###### 

Association between asthma and related traits

  Trait                         OR (95% CI)         *p*
  ----------------------------- ------------------- -----------
  Total serum IgE               1.60 (1.24, 2.07)   \< 0.0001
  Atopy                         3.09 (1.39, 6.87)   0.006
  Food allergen test positive   2.04 (0.99, 4.20)   0.053
  Eosinophilia                  3.56 (1.30, 9.73)   0.013

† Logistic regression employed to estimate the Odds Ratio (OR) and 95% Confidence Interval (CI) of the Odds Ratio; *p: p-value*.

SNP associations
----------------

The number of subjects analyzed for each phenotype was 129, 138, 136, 140, and 140, for asthma, atopy, testing positive for food allergy, eosinophilia, and total serum IgE phenotypes, respectively. Statistically significant associations were only observed for the asthma phenotype, for SNPs in *GSTM1, MS4A2*, and *GSTP1*, after correction for multiple testing (Figure [1](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). *GSTM1*rs412543 C carriers were almost 3 times as likely to have asthma compared to individuals without the C allele. All of the *MS4A2*SNPs evaluated were associated with a lower odds of asthma, and the associations were statistically significant for rs556917 A/T, rs502581 C/A, and rs502419 G/A. Strong linkage disequilibrium existed across *MS4A2*, in particular for rs556917, rs502581, and rs502419 (r^2^\> 0.7, Figure [2](#F2){ref-type="fig"}). The tightly linked *GSTP1*SNPs rs1871042 C/T and rs947865 C/A (Figure [3](#F3){ref-type="fig"}) were associated with a lower odds of asthma.

![**Segmented Manhattan plot displaying SNP associations with asthma/allergy traits**. Negative log-transformed *p*-value (-log(*p*)) indicative of statistical significance for the association between each SNP and trait, where higher -log(*p*) values correspond to greater statistical significance. SNPs significant based on FDR \< 0.25 indicated with a black box.](1471-2350-12-25-1){#F1}

###### 

Association between SNPs and asthma

  Gene      Chr   Position    SNP              MAF    Odds Ratio (95% CI)   *Unadjusted p*   *FDR*
  --------- ----- ----------- ---------------- ------ --------------------- ---------------- -----------
  *GSTM1*   1     108482748   rs17672 C/T      0.16   1.47 (0.71, 3.04)     0.302            0.673
            1     110031467   rs412543 G/C     0.12   2.89 (1.14, 7.32)     0.025            **0.207**
            1     110031479   rs3815029 G/C    0.17   0.69 (0.33, 1.42)     0.312            0.673
                                                                                             
  *MS4A2*   11    59612059    rs574700 C/T     0.18   0.50 (0.23, 1.07)     0.042            0.249
            11    59612604    rs1441586 T/C    0.43   0.56 (0.25, 1.25)     0.114            0.390
            11    59615288    rs556917 A/T     0.34   0.47 (0.22, 0.97)     0.028            **0.207**
            11    59616754    rs502581 C/A     0.26   0.50 (0.24, 1.02)     0.030            **0.207**
            11    59622751    rs502419 G/A     0.24   0.45 (0.21, 0.93)     0.028            **0.207**
                                                                                             
  *GSTP1*   11    67106475    rs6591256 A/G    0.43   0.66 (0.31, 1.38)     0.162            0.495
            11    67107508    rs17593068 G/T   0.43   0.71 (0.34, 1.50)     0.169            0.495
            11    67109265    rs1695 A/G       0.44   1.61 (0.75, 3.42)     0.208            0.569
            11    67110420    rs1871042 C/T    0.30   0.44 (0.22, 0.91)     0.010            **0.207**
            11    67110982    rs947895 C/A     0.29   0.44 (0.22, 0.91)     0.015            **0.207**

† 41 SNPs evaluated as well as the *GSTT1*deletion. Logistic regression adjusted for sex and performed in *PLINK*version 1.06. SNP major allele/minor allele noted, in that order. MAF: Minor allele frequency; Chr: Chromosome, 95% CI: 95% Confidence Intervals of the odds ratio, *p: p-value*. Statistical significance after correction for multiple comparisons evaluated using False Discovery Rate (FDR). FDR ≤ 0.25 denoted statistically significant associations, marked in bold. Data presented for genes with one or more statistically significant associations. Models included 129 individuals.

![**Linkage disequilibrium (LD) observed across SNPs of *MS4A2*. r^2^values displayed in triangle plot represent strength of LD between SNPs**. Color scheme: white (weakest LD): D\' \< 1, LOD \< 2; blue: D\' = 1, LOD \< 2; shades of pink/red: D\' \< 1, LOD≠2; bright red (strongest LD): D\' = 1, LOD≠2. SNPs in study population indicated in green, HapMap SNPs in black. HapMap data specific to the individuals of African ancestry from the South West United States (ASW) population.](1471-2350-12-25-2){#F2}

![**Linkage disequilibrium (LD) observed across SNPs of *GSTP1***. r^2^values displayed in triangle plot represent strength of LD between SNPs. Color scheme: white (weakest LD): D\' \< 1, LOD \< 2; blue: D\' = 1, LOD \< 2; shades of pink/red: D\' \< 1, LOD≠2; bright red (strongest LD): D\' = 1, LOD≠2. SNPs in study population indicated in green, HapMap SNPs in black. HapMap data specific to the individuals of African ancestry from the South West United States (ASW) population.](1471-2350-12-25-3){#F3}

Haplotype associations
----------------------

The statistically significant SNP associations were complimented by gene-specific haplotype analyses, presented in Table [3](#T3){ref-type="table"}. *GSTM1*haplotypes CCG and CGC corresponding to SNPs rs17672, rs412543, and rs3815029, showed contrasting direction of associations with asthma. Specifically, the CCG haplotype was associated with a 3 fold increase in the odds of asthma whereas the CGC haplotype corresponded to an Odds Ratio (OR) of 0.36. The frequency of both of these haplotypes was approximately 10%. The *MS4A2*TCTAA haplotype offered a protective association with asthma compared to the CTACG (Table [3](#T3){ref-type="table"}). Sliding window analyses in *Haplostats*indicated that 3 tightly linked SNPs (*MS4A2*-ACG haplotype for rs556917, rs502581, and rs502419) drove the association with asthma (simulated *p*values = 0.03, 0.033, 0.026 for rs556917, rs502581, and rs502419, respectively, 1000 simulations). *GSTP1*AGATA (OR = 0.28, *p*= 0.027) and *GSTP1*AGGCC (OR = 2.23, *p*= 0.018) displayed contrasting associations with asthma. Sliding window analyses in *Haplostats*identified loci rs1695, rs1871042, and rs947895 to be the strongest SNPs driving the associations, based on the maximum scan statistics. However, the locus-scan statistic *p*values and max-stat simulated global *p*value were not statistically significant (*p*\> 0.05 for 1000 simulations).

###### 

Association between haplotypes and asthma

  Gene      Chr   BP1         BP2         SNP1        SNP2        Haplotype   Frequency   Odds Ratio   *Unadjusted p*   *FDR*
  --------- ----- ----------- ----------- ----------- ----------- ----------- ----------- ------------ ---------------- -----------
  *GSTM1*   1     108482748   110031479   rs17672     rs3815029   CCG         0.10        3.01         0.05             **0.210**
            1     108482748   110031479   rs17672     rs3815029   CGC         0.11        0.36         0.04             **0.209**
            1     108482748   110031479   rs17672     rs3815029   CGG         0.64        0.82         0.506            0.781
            1     108482748   110031479   rs17672     rs3815029   TCC         0.01        4.48         0.298            0.626
            1     108482748   110031479   rs17672     rs3815029   TGC         0.05        1.58         0.508            0.781
            1     108482748   110031479   rs17672     rs3815029   TGG         0.09        1.18         0.759            0.839
                                                                                                                        
            11    59612059    59622751    rs574700    rs502419    CCACG       0.08        1.63         0.286            0.626
            11    59612059    59622751    rs574700    rs502419    CCTAA       0.07        0.86         0.758            0.839
            11    59612059    59622751    rs574700    rs502419    CCTCA       0.01        1.02         0.982            0.982
  *MS4A2*   11    59612059    59622751    rs574700    rs502419    CCTCG       0.07        0.78         0.595            0.781
            11    59612059    59622751    rs574700    rs502419    CTACG       0.57        1.58         0.114            0.399
            11    59612059    59622751    rs574700    rs502419    TCTAA       0.14        0.43         0.032            **0.209**
            11    59612059    59622751    rs574700    rs502419    TCTAG       0.04        1.04         0.96             0.982
                                                                                                                        
            11    67106475    67110982    rs6591256   rs947895    AGACC       0.27        1.2          0.519            0.781
            11    67106475    67110982    rs6591256   rs947895    AGATA       0.07        0.28         0.027            **0.209**
            11    67106475    67110982    rs6591256   rs947895    AGATC       0.01        0.56         0.642            0.793
  *GSTP1*   11    67106475    67110982    rs6591256   rs947895    AGGCC       0.21        2.23         0.018            **0.209**
            11    67106475    67110982    rs6591256   rs947895    GTACC       0.18        0.82         0.573            0.781
            11    67106475    67110982    rs6591256   rs947895    GTATA       0.02        0.19         0.201            0.603
            11    67106475    67110982    rs6591256   rs947895    GTGCC       0.03        1.59         0.562            0.781
            11    67106475    67110982    rs6591256   rs947895    GTGTA       0.19        0.70         0.288            0.626

† Logistic regression adjusted for sex and performed in PLINK version 1.06. SNP1: SNP of left-most (5\') SNP in haplotype, SNP2: SNP of right most (3\') SNP in haplotype. ß: Beta estimate, *p: p-*value. Statistical significance after correction for multiple comparisons evaluated using False Discovery Rate (FDR). FDR ≤ 0.25 denoted statistically significant associations, marked in bold. Models included 129 individuals.

Chromosome-wide haplotype association
-------------------------------------

Chromosome 11 haplotypes displayed the strongest statistically significant associations with asthma and were subsequently evaluated for a chromosome-wide haplotype effect on asthma. The chromosome 11 haplotype CTACGAGGCC (corresponding to *MS4A2*rs574700, rs1441586, rs556917, rs502581, rs502419 and *GSTP1*rs6591256, rs17593068, rs1695, rs1871042, rs947895) was associated with a nearly five-fold increase in the odds of asthma (OR = 4.8, *p*= 0.007). The frequency of this haplotype was 10% in our population. At the time this work was conducted, *PLINK*software did not include computation of 95% confidence intervals for haplotype associations.

Genetic risk score
------------------

SNPs significantly associated with elevated odds of asthma were evaluated in concert by constructing a genetic risk score. This score combined data for the following SNPs: *GSTM1*rs412543, *MS4A2*rs556917 and rs502419 (tagging rs502581), and *GSTP1*rs947895 (tagging rs1871042). The *MS4A2*SNPs rs556917 and rs502419 did not tag each other, and were both included in the GRS. This was consistent with modified settings of the *Tagger*program (data not shown).

The genetic risk score ranged from 0 to 7 variant alleles carried by an individual and approximated normal distribution (W = 0.98, Z = 1.142, *p*= 0.126). The GRS was statistically significantly associated with a higher odds of asthma (OR = 1.61, 95% Confidence Interval (CI) = 1.21, 2.13; *p*= 0.001). Incremental increases in the GRS corresponded to higher total serum IgE and higher odds of atopy and eosinophilia, but these results were not statistically significant.

Discussion and Conclusion
=========================

Genetic associations with asthma
--------------------------------

In this study, we evaluated previously identified variants for association with asthma/allergy among African American children living in Detroit, Michigan. Of the 41 SNPs evaluated in statistical analyses, SNPs within *GSTM1, MS4A2*, and *GSTP1*were associated with asthma. Chromosome 11 SNPs, in particular the *MS4A2*-CTACG/*GSTP1*-AGGCC haplotype, played the greatest role in genetic predisposition to asthma in this population. When risk alleles were evaluated in concert using a genetic risk score, SNPs predisposing individuals to asthma exhibited an expected cumulative effect. The genetic risk score (or genetic risk index) has been employed to understand individual susceptibility to obesity \[[@B60]\], cardiovascular disease \[[@B61]-[@B63]\], coronary artery disease \[[@B64]\], diabetes \[[@B58]\], serum uric acid concentration \[[@B65]\], multiple sclerosis \[[@B66]\], and rheumatoid arthritis \[[@B67]\]. Some studies have evaluated a weighted GRS, where each SNP included in the score is weighted by a beta coefficient from a meta-analysis of SNPs associated with disease, as was done in Cornelis et al., 2009 \[[@B58]\]. To our knowledge, a meta-analysis providing sufficient data for the construction of a GRS for asthma/allergy was not available at the time these analyses were completed.

Functional significance and role in asthma etiology
---------------------------------------------------

The observation that variation in *MS4A2*was significantly associated with a higher risk of asthma is consistent with *MS4A2*\'s involvement in allergic disease \[[@B32]\]. SNPs within *MS4A2*have previously been associated with atopy via regulation of Fc epsilon RI expression \[[@B68]\]. A recent study among Australians, Dutch, and Danish individuals found weak evidence for rs502581 to be associated with IgE \[[@B69]\]. We did not identify significant associations between this SNP and IgE in our study population, but we note the direction of effect was consistent with what has been reported, the A allele corresponding to lower IgE levels (β = -0.14, 95% CI = -0.64, 0.36, *p*= 0.587) and the T allele corresponding to higher IgE levels. In our study population, the A allele was the risk allele tested due to default parameters in *PLINK*.

*GSTP1\'s*role in xenobiotic metabolism and antioxidation is also consistent with asthma etiology, although it is likely to play a different role in asthma pathogenesis compared to *MS4A2*. Variation in this gene may result in differing metabolism of environmental toxins across individuals. We speculate that individuals with multiple risk alleles across *MS4A2*and *GSTP1*genes are more susceptible to harmful effects of environmental toxins, and that this sensitivity may contribute to the development of asthma or asthma exacerbation. Additional investigations incorporating environmental data are required to confirm this hypothesis. We did not observe significant associations between the functional sequence variant in *GSTP1*at codon 15 (Ile105Va - rs1695). The role of this variant in asthma/allergy has been inconsistently reported in the literature, possibly due to heterogeneity of environmental exposures \[[@B70]\]. Other studies have reported that this variant is tagged by rs947895 in White populations \[[@B71]\], which corresponded to a significant association with asthma in our study. However, the genetic variation that is tagged by this SNP in our African ancestry population may be less than what has been reported in other ethnic groups.

Supporting analyses
-------------------

Asthma is a complex trait that is variably defined across studies. Thus, we compared our definition of asthma with slightly variable phenotypes, current asthma (yes/no) and asthma medication use (yes/no) based on parental questionnaire data. The association between SNPs, haplotypes, or the GRS and asthma was consistent when evaluated for current asthma or medication use, with regards to the direction of association (odds ratio estimates) and statistical significance (*p*-values).

Limitations
-----------

Our study population was largely atopic (67%) and over 39% tested positive for response to a panel of food allergens. These statistics limit the generalizability of our findings to children of similar age in the United States. However, the associations discussed here may be informative for other vulnerable populations or high risk groups where the prevalence of asthma is high.

The sample size of 141 limited our power to detect statistically significant associations after correction for multiple testing. Because of the small number of SNPs genotyped, we were unable to capture much of the genomic landscape relevant to the phenotypes of interest. Thus, unmeasured genetic risk factors that play a role in asthma/allergy susceptibility were inadequately captured in this study. The small number of SNPs also limited our ability to comprehensively assess population stratification through principal components analysis using genome wide data or ancestry informative markers (AIMS). We relied on self-reported ethnicity to reduce issues of genetic heterogeneity. For these reasons, caution is warranted when assessing the generalizability of our study findings to other independent cohorts.

The candidate genes were selected for genotyping before the publication of the *DENND1B*association with asthma in a genome wide association study of African-ancestry populations \[[@B72]\]. *DENND1B*is expressed by natural killer cells and dendritic cells, encoding a protein that interacts with the TNF-α receptor. Although we do not present data on this gene, we note that significant associations between the measured *TNF-α*SNPs and asthma were not observed in this study population.

Future directions
-----------------

This report did not incorporate environmental risk factors for asthma. It is likely that environmental agents interact with a person\'s genetic predisposition or provide an additional burden on the genetically susceptible group, increasing the odds of asthma/allergy or exacerbating symptoms. Future work should incorporate a greater number of subjects and SNPs, and evaluate SNPs and environmental exposures in concert as they relate to asthma, asthma severity and asthma exacerbation. It remains particularly important to test and validate associations in populations with a high disease burden.
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